95790-95-7

Upstream product

• 95790-94-6 Acetic acid (4S,5R)-5-acetoxymethyl-1,3-dibenzyl-2-oxo-imidazolidin-4-ylmethyl ester 
• 64-19-7 acetic acid 
• 56198-32-4 cis-1,3-dibenzyl-4,5-dihydroxymethyl-imidazolidin-2-one 
• 108-22-5 Isopropenyl acetate 
• 141-78-6 ethyl acetate 
• 56198-73-3 dimethyl cis-1,3-dibenzyl-2-oxoimidazolidine-4,5-dicarboxylate 
• 108-05-4 vinyl acetate 
• 108-24-7 acetic anhydride 

Downstream Products

• 95790-97-9 Acetic acid (4S,5R)-1,3-dibenzyl-5-methoxymethoxymethyl-2-oxo-imidazolidin-4-ylmethyl ester 
• 87585-00-0 (4S,5R)-1,3-dibenzyl-5-hydroxymethyl-2-oxoimidazolidine-4-carboxylic acid lactone 
• 95790-98-0 (4S,5R)-1,3-Dibenzyl-4-hydroxymethyl-5-methoxymethoxymethyl-imidazolidin-2-one 
• 95790-99-1 cis 1,3-Dibenzyl-4-hydroxy-2,3,3a,4,6,6a-hexahydro-furo<3,4-d>imidazol-2-one 
• 28092-62-8 (3aS,6aR)-1,3-dibenzyltetrahydro-1H-furo[3,4-d]imidazole-2,4-dione 

Relevant academic research and scientific papers

Chemoenzymatic synthesis of d-biotin intermediate lactone via lipase-catalyzed desymmetrization of meso diols

A chemoenzymatic methodology for the asymmetric synthesis of d-biotin intermediate lactone ((3aS, 6aR)-tetrahydro-1,3-dibenzylhexahydro-1H-Furo[3,4-d] imidazole-2,4-dione) 1 has been demonstrated. The key step of the synthetic routes is Lipozyme RM IM catalyzed desymmetrization of meso-diols 3. The highest enantiomeric excess (e.e. > 98%) and yield (>90%) of the product was achieved with Lipozyme RM IM in Dioxane/Toluene (1:3, v/v) at 35 C. Furthermore, Lipozyme RM IM showed an excellent operational stability, retaining above 80% of the initial activity after 10 cycles of reaction. d-Biotin intermediate lactone 1 was obtained subsequently by Jones oxidation, basic hydrolysis and lactonization.

BIFUNCTIONAL CHIRAL SYNTHONS VIA BIOCHEMICAL METHODS. 4. CHIRAL PRECURSORS TO (+)-BIOTIN AND (-)-A-FACTOR.

The chirons 3 and 4, derived from enzymic enantioselective hydrolysis of 1 and 2, are converted into the chiral lactones 5 and 6, key precursors to (+)-biotin and (-)-A-factor, respectively.